Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers

Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force

(2013) Mark Helfand et al.   ANNALS OF INTERNAL MEDICINE

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

(2012) Jemma C. Hopewell et al.   EUROPEAN HEART JOURNAL

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

(2012) Harshal A. Deshmukh et al.   JOURNAL OF LIPID RESEARCH

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial

(2011) H. M. Colhoun et al.   DIABETES

Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients

(2010) Kwang Kon Koh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

RETRACTED: Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers

(2010) Benoit J. Arsenault et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

B-Type Natriuretic Peptides and Cardiovascular Risk

(2009) Emanuele Di Angelantonio et al.   CIRCULATION

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study

(2009) Jacques Bonnet et al.   CLINICAL THERAPEUTICS

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison Effect of Atorvastatin (10 versus 80 mg) on Biomarkers of Inflammation and Oxidative Stress in Subjects With Metabolic Syndrome

(2008) Uma Singh et al.   AMERICAN JOURNAL OF CARDIOLOGY

C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction

(2008) Paul M Ridker et al.   CIRCULATION

Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death

(2008) B. M. Scirica et al.   CLINICAL CHEMISTRY

The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study

(2008) M. J. West et al.   EUROPEAN HEART JOURNAL

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia

(2007) Marijn C. Meuwese et al.   ATHEROSCLEROSIS